Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lin Shen

Showing results (1531-1540 of 1,553) with videos related to

Pageof 156
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 10, 2021
Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphomaDan Liu, Chunguang Ma, Ping Lu, et al.
Nature Medicine|July 16, 2025
CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trialJia Liu, Jianwei Yang, Yuping Sun, et al.
The Lancet. Gastroenterology & Hepatology|December 4, 2025
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRAS<sup>G12C</sup> mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trialsJian Li, Zhenghang Wang, Jing Huang, et al.
Innovation (Cambridge (Mass.))|July 9, 2026
Chinese consensus on first-line precision therapy for advanced gastric cancerXiaotian Zhang, Weiqi Sheng, Tong Xie, et al.
Eclinicalmedicine|May 27, 2024
Effects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 studyZhihao Lu, Li Kong, Buhai Wang, et al.
Nature Communications|May 10, 2018
Author Correction: A proteomic landscape of diffuse-type gastric cancerSai Ge, Xia Xia, Chen Ding, et al.
Nature Medicine|June 1, 2024
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trialFeng Wang, Lin Shen, Weijian Guo, et al.
Nature Communications|March 10, 2018
A proteomic landscape of diffuse-type gastric cancerSai Ge, Xia Xia, Chen Ding, et al.
Nature Medicine|June 1, 2026
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trialZhi Peng, Tianshu Liu, Hua Wang, et al.
The Lancet. Oncology|July 12, 2021
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trialXiaotian Zhang, Han Liang, Ziyu Li, et al.
Pageof 156

Showing results (1531-1540 of 1,553) with videos related to

Sort By:
Pageof 156
European Journal of Cancer (Oxford, England : 1990)|March 10, 2021
Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphomaDan Liu, Chunguang Ma, Ping Lu, et al.
Nature Medicine|July 16, 2025
CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trialJia Liu, Jianwei Yang, Yuping Sun, et al.
The Lancet. Gastroenterology & Hepatology|December 4, 2025
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRAS<sup>G12C</sup> mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trialsJian Li, Zhenghang Wang, Jing Huang, et al.
Innovation (Cambridge (Mass.))|July 9, 2026
Chinese consensus on first-line precision therapy for advanced gastric cancerXiaotian Zhang, Weiqi Sheng, Tong Xie, et al.
Eclinicalmedicine|May 27, 2024
Effects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 studyZhihao Lu, Li Kong, Buhai Wang, et al.
Nature Communications|May 10, 2018
Author Correction: A proteomic landscape of diffuse-type gastric cancerSai Ge, Xia Xia, Chen Ding, et al.
Nature Medicine|June 1, 2024
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trialFeng Wang, Lin Shen, Weijian Guo, et al.
Nature Communications|March 10, 2018
A proteomic landscape of diffuse-type gastric cancerSai Ge, Xia Xia, Chen Ding, et al.
Nature Medicine|June 1, 2026
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trialZhi Peng, Tianshu Liu, Hua Wang, et al.
The Lancet. Oncology|July 12, 2021
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trialXiaotian Zhang, Han Liang, Ziyu Li, et al.
Pageof 156